Farzin Haque
Stock Analyst at Jefferies
(1.30)
# 3,704
Out of 5,078 analysts
12
Total ratings
41.7%
Success rate
-2.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterated: Buy | $50 → $48 | $18.26 | +162.87% | 2 | Sep 9, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $3.27 | +175.23% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Reiterated: Buy | $57 → $45 | $27.99 | +60.77% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $48.13 | -12.74% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $4.57 | n/a | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.9801 | n/a | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $10 → $6 | $1.68 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Sep 9, 2026
Reiterated: Buy
Price Target: $50 → $48
Current: $18.26
Upside: +162.87%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.27
Upside: +175.23%
Vera Therapeutics
Nov 26, 2025
Reiterated: Buy
Price Target: $57 → $45
Current: $27.99
Upside: +60.77%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $48.13
Upside: -12.74%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $4.57
Upside: n/a
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.9801
Upside: n/a
Pyxis Oncology
Mar 18, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $1.68
Upside: n/a